What should actuaries be doing in the run-up to a post-aging world? Aubrey D.N.J. de Grey Department of Genetics, University of Cambridge Reprints, general.

Slides:



Advertisements
Similar presentations
I want LONGER Telomeres Oprah Winfrey -November 1 st, 2007 Long Telomeres Short Telomeres.
Advertisements

Chief Science Officer, SENS Foundation
Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,
Replicative aging in budding yeast cells Dr. Michael McMurray Dept. Molecular & Cell Biology.
Dr Aubrey de Grey Chief Science Officer Repairing the aging brain: the SENS approach Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer, SENS Foundation.
 When customers are unhappy with service they have two options:  They can say something (talkers)  Or they can walk away (walkers) © Jacqui Knight.
Biogerontologists’ duty to discuss timescales publicly Aubrey D.N.J. de Grey Department of Genetics, University of Cambridge.
3 Aging 1950 ’ s – Believed that cultivated cells could grow forever If not, then it was a result of a culturing deficiency – In 1943, a cancer cell.
Chapter 11 Newborn Screening. Introduction Newborns can be screened for an increasing variety of conditions on the principle that early detection can.
The foreseeability of real anti-aging medicine: Faith, rational design, and our duty to abandon dogmatism just this once Aubrey D.N.J. de Grey Department.
TELOMERES What are they? Why are they important? Telomere shortening and the end-replication problem Telomerase Telomere hypothesis of aging.
TOPICS IN (NANO) BIOTECHNOLOGY Lecture 3 16th October, 2006 PhD Course.
3 Aging 1950 ’ s – Believed that cultivated cells could grow forever If not, then it was a result of a culturing deficiency – In 1943, a cancer cell.
Dr Aubrey de Grey Chief Science Officer Prospects for defeating aging altogether Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer, SENS Foundation
Prospects for extending healthy life - a lot Aubrey D.N.J. de Grey, Ph.D. Chairman and CSO, Methuselah Foundation Lorton, VA, USA and Cambridge, UK
Prospects for defeating aging altogether Aubrey D.N.J. de Grey, Ph.D. Chairman and CSO, Methuselah Foundation Lorton, VA, USA and Cambridge, UK
Extension Article by Dr Tim Kenny
1 Biomedical Sciences Public and Environmental Health Regenerative Medicine Translational Research.
Normal Cells vs. Cancer Cells 1
NS 1300 Emergence of Modern Science Biotechnology.
Cellular Senescence What is it? What causes it? Why is it important (cancer and aging)?
AGING ……. What is it, why does it happen, what's to be done about it (if anything)?
Clinical trials methodology group Simon Gates 9 February 2006.
Cellular Senescence What is it? What causes it? Why is it important (cancer and aging)?
Unit 2: Population.
Gene Cloning -Techniques -Ethics -Uses -Consequences.
KEY CONCEPT Genetics provides a basis for new medical treatments.
Medical Biotechnology
Premature human aging: t he progerias A&S Jim Lund Reading: Genetic alterations in accelerated ageing syndromes Do they play a role in natural ageing?
Drug Testing GRADE C Describe the main steps in testing a new drug.
Is life extension an enhancement? Yes and no and why that’s useful
M USCULAR D YSTROPHY By: Collin Lowe. C AUSES Muscular Dystrophy is inherited in an X-linked recessive pattern, meaning that the mutated gene that causes.
Why Leave a Legacy When You Can Live Your Legacy?.
CMPT 880/890 Arguments. Outline Arguments What should be an argument and what shouldn’t? Claims Reasons Evidence.
My role Being part of the core MAGIC team for primary care Imbedding shared decision making into the culture of the surgery Writing patient decision aids(PDAs)
Evolution of Aging and Other Life History Characteristics Chapter 13 1)Life history, energy allocation, and trade-offs 2)What is the Rate-of-Living Theory.
The aging phenotype: cellular aspects A&S Jim Lund.
The feasibility and desirability of indefinite youth: recent advances from unexpected quarters Aubrey de Grey Department of Genetics, University of Cambridge.
Well, I am former president and California governor, Ronald Reagan. I died in 2004 from Alzheimer’s Disease. You might say I’m the world’s most famous.
Aging-prevention paradigm: against the idle brain Natallia Aniskovich B.R.A.I.N. Interdisciplinary Center for Neuroscience University of Trieste Trieste.
Dr Aubrey de Grey Chief Science Officer Prospects for defeating aging altogether Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer, SENS Foundation
New extramural projects funded by MF Aubrey D.N.J. de Grey, Ph.D. Chairman and CSO, Methuselah Foundation Lorton, VA, USA and Cambridge, UK
Universal aspects of aging A&S Jim Lund “Age is not a particularly interesting subject. Anyone can get old. All you have to do is live long enough.”
The Science of Ageing Fergus Doubal 12 th December 2006 Concepts Impact on the organism Demographic shifts in populations.
The Human Genome Project Eric Lander PhD Director Whitehead Center for Genome Research Cambridge, MA Eric Topol MD Provost and Chief Academic Officer Chairman.
KEY CONCEPT Cell cycle regulation is necessary for healthy growth.
CANCER - a public health issue. epidemiology the study of the patterns, causes, and effects of health and disease conditions in defined populations informs.
TELOMERES &TELOMERASE 18 th Lecture Gihan E-H Gawish, MSc, PhD Ass. Professor Molecular Genetics and Clinical Biochemistry Molecular Genetics and Clinical.
Rationalizing the New Healthcare Paradigm Scientific Agenda vs. Patient Imperatives Scientific Agenda vs. Patient Imperatives.
Cellular Senescence What is it? What causes it? Why is it important (cancer and aging)?
Biomedical Longevity Revolution and its Consequences Dr. Leonid A. Gavrilov, Ph.D. Dr. Natalia S. Gavrilova, Ph.D. Center on Aging NORC and the University.
Introduction to Science. Science is two things: A Body of Knowledge – FACT: your body usually has 206 bones, depending on how you count them – This is.
Unit B Animal Science and The Industry. Problem Area 6 Meeting Environmental Requirements of Animals.
Big Data in Biology: A focus on genomics. Bioinformatics and Genomics O Applications: O Personalized cancer medicines O Disease determination O Pathway.
Biological Theories of Aging. Four Criteria on Biological Theories on Aging  Universal process: all members of a species must experience it  Process.
13 Genetics of Aging 1950 ’ s – Believed that cultivated cells could grow forever If not, then it was a result of a culturing deficiency.
“Vintage people” are possible, just like vintage cars Dr. Aubrey de Grey Methuselah Foundation, Cambridge, UK Website:
Medical advances that prolong life are generally good Medical treatments these days are worth the costs Radical life extension would be good for society.
SENS Research Foundation
Seminar May 21st 2015 “Rejuvenation biotechnology: the sweet spot between prevention and treatment of aging” Aubrey de Grey Chief Science Officer,
Can we end aging? 林詩茵 邱淑敏 王雅佳 袁樂宜.
KEY CONCEPT Genetics provides a basis for new medical treatments.
KEY CONCEPT Genetics provides a basis for new medical treatments.
KEY CONCEPT Genetics provides a basis for new medical treatments.
Hurdles in Treating Aging as a Disease for Drug Development
KEY CONCEPT Genetics provides a basis for new medical treatments.
Component 11 Unit 7: Building Order Sets
KEY CONCEPT Genetics provides a basis for new medical treatments.
KEY CONCEPT Genetics provides a basis for new medical treatments.
Presentation transcript:

What should actuaries be doing in the run-up to a post-aging world? Aubrey D.N.J. de Grey Department of Genetics, University of Cambridge Reprints, general info:

Structure of this talk - definitions, milestones and strategies - why the “War On Aging” may be only a decade away - why it may be a very short war - why we may also “win the peace” very quickly - what this means for those projecting population trends: what CMIB et al. can do to make (4) a reality

Definitions Senescence (Anon): the process that progressively reduces an organism’s remaining life expectancy Negligible senescence (Finch 1990): absence, in a population, of a degree of senescence sufficient to be statistically detectable by examining its age distribution Engineered negligible senescence (de Grey 1999): the biotechnological conversion of a population that exhibits statistically detectable senescence into one that does not

t 1 t 2 t 3 t 4 t 5 t 6 : late-onset human ENS (LOHENS) ubiquitous A brief “history” of engineered negligible senescence (ENS)

Q: What do people need, to start caring about life extension? A: Laboratory results that they can identify with: - life extension in mammals - treatment initiated late in life

t 1 : important components of human aging all known to be so t 2 : feasible plan for “Robust Mouse Rejuvenation” described t 3 : RMR developed: remaining LE of 2yo mice trebled LOHENS widely seen as foreseeable, WOA begins t 5 : LOHENS developed, some people are in “clinical trials” t 6 : late-onset human ENS (LOHENS) ubiquitous A brief “history” of engineered negligible senescence (ENS) t4:t4: t5:t5: t6:t6:

Three paradigms for intervention Gerontology Engineering Geriatrics Metabolism Damage Pathology Claim: only the “engineering” approach can achieve substantial extension of human healthspan any time soon

2. Why the War On Aging may be only a decade away

Metabolism Damage Pathology: The seven deadly things -- or, t 1 was 1982 Respiration (oxidation) Carbohydrate metabolism (glycation) Cell turnover (mutations, telomere shortening, dysregulation, stem cell depletion) Etc, etc, etc Cell loss/atrophy Nuclear mutations and epimutations mtDNA mutations Cell senescence AGE crosslinks Extracellular junk Lysosomal junk Er.... that’s it! Neurodegeneration Atherosclerosis Cancer Diabetes Hormone decline Blindness Immune decline Etc, etc, etc

t 2 is now Damage rising with ageReversible or obviatable by Cell loss, cell atrophyExercise, cell therapy, growth factors Extracellular junkPhagocytosis by immune stimulation Extracellular crosslinksALT-711, other AGE-breakers Cell senescenceImmune ablation of senescent cells mtDNA mutationsAllotopic expression of 13 proteins Lysosomal junkTransgenic microbial hydrolases Nuclear [epi]mutations (only cancer matters) Telomerase/ALT gene deletion plus periodic stem cell reseeding ****** t 2 : feasible plan for “Robust Mouse Rejuvenation” described

A brief “history” of engineered negligible senescence (ENS) t 1 ~ 1982: important components of human aging all known to be so t 2 ~ 2002: feasible plan for “Robust Mouse Rejuvenation” described t 3 ~ ????-????: RMR developed: remaining LE of 2yo mice trebled t 4 ~ ????-????: LOHENS widely seen as foreseeable, WOA begins t 5 ~ ????-????: LOHENS developed, people are in “clinical trials” t 6 ~ ????-????: late-onset human ENS (LOHENS) ubiquitous ????-????:

Biogerontologists Voters, shareholders Government, industry Media Ballot box Peer review, short-termism t 3 = t y: RMR developed: remaining LE of 2yo mice trebled t 4 = t y: LOHENS widely seen as foreseeable, WOA begins Will WOA begin in one decade, or two? 3-5y:

A brief “history” of engineered negligible senescence (ENS) t 1 ~ 1982: important components of human aging all known to be so t 2 ~ 2002: feasible plan for “Robust Mouse Rejuvenation” described t 3 ~ : RMR developed: remaining LE of 2yo mice trebled t 4 ~ : LOHENS widely seen as foreseeable, WOA begins t 5 ~ ????-????: LOHENS developed, people are in “clinical trials” t 6 ~ ????-????: late-onset human ENS (LOHENS) ubiquitous : ????-????:

3. Why it may be a very short war

How long will the war on aging last? t 5 = t ???y: LOHENS developed, people are in “clinical trials” t 1 ~ 1982: important components of human aging all known to be so t 2 ~ 2002: feasible plan for “Robust Mouse Rejuvenation” described t 3 ~ : RMR developed: remaining LE of 2yo mice trebled t 4 ~ : LOHENS widely seen as foreseeable, WOA begins t 5 ~ 2020-????: LOHENS developed, people are in “clinical trials” t 6 ~ ????-????: late-onset human ENS (LOHENS) ubiquitous : 2020-????: ????-????: 5-???y:

Q: Aren’t there lots of aspects of human aging that mice don’t get? A: yes -- but as soon as something is implemented in mice, it can be translated incrementally to humans: to suitably humanised mice, to dogs, to monkeys. With late-onset interventions (and ample funding -- remember WOA is in progress at this point), this is relatively quick.

Q: How could LOHENS (complete control of human aging) possibly arrive so soon after WOA begins? A: bootstrapping We age very slowly. Even a doubling of the remaining life expectancy of 60-year-olds, such that at 80 they are still physiologically 60 but then they decline at present rate, allows 20 years (a very long time in science!) to develop a doubling of the remaining life expectancy of those same people at 80, etc, etc.

Q: But won’t life-extended people be at risk from yet-unknown causes, which will take time to research/cure? A: monkeys It is very unlikely that humans will ever suffer at age N from anything that monkeys don’t get by at least age N/2 given the same medical care. We will thus have a long (and increasing!) lead time to develop cures for as yet unknown age-related problems before any human ever exhibits them.

Q: But aren’t small-looking steps sometimes surprisingly hard? (e.g.: we had Concorde and moon walks 30 years ago, but we still lack space tourism and Mars walks) A: Progress ceased only when we couldn’t be bothered. This seems unlikely with aging once we have the bit between our teeth

4. Why we may also “win the peace” very quickly

How long will it take to “win the peace”? t 6 = t y: late-onset human ENS (LOHENS) ubiquitous t 1 ~ 1982: important components of human aging all known to be so t 2 ~ 2002: feasible plan for “Robust Mouse Rejuvenation” described t 3 ~ : RMR developed: remaining LE of 2yo mice trebled t 4 ~ : LOHENS widely seen as foreseeable, WOA begins t 5 ~ 2020-????: LOHENS developed, people are in “clinical trials” t 6 ~ 2025-????: late-onset human ENS (LOHENS) ubiquitous : 2020-????: 2025-????: 5-???y:

With infinite funds and infinitely many medical personnel... the situation would be simple enough: nothing would stop us from providing rejuvenation therapy for free, to everyone, without delay. Arguments stressing the dangers of doing so (overpopulation, boredom, tyrants reigning forever) will be unpersuasive, to say the least. But funds and expertise will be finite

The history of distribution of medical care: not a useful precedent Difference #1: public pressure will force the compulsory purchase of any patent that risks retarding universal access Difference #2: in the long term, rejuvenation therapy pays for itself, however expensive it is, by wealth produced by the beneficiary

Inference: the sooner we start setting funds aside and training more medics, the better Danger: un-meetable demand (starting at t 4, the start of the WOA) for traditional medical care to help people make the cut Danger: strife between wealthy “immortal” nations and poor “subhuman” nations in a post-9/11 world

Conclusion, for biogerontologists Straw polls at IABG 10, 22/9/03: 1) Most of you think I might be right about t 3 2) Most of you think we shouldn’t discuss t 5, t 6 Are these views compatible?

Conclusion, for actuaries The best possible scenario will only occur with: 1) luck with the science 2) wisdom of policy-makers 3) forward planning to provide enough resources How many people will demand rejuvenation in year X? How many people will demand traditional medicine? How much will it cost and how soon will it be repaid?